U.S., July 17 -- ClinicalTrials.gov registry received information related to the study (NCT07068932) titled 'Phase I Clinical Study of SHR-4506 Injection in Patients With Malignant Tumors' on July 07.
Brief Summary: The study is being conducted to evaluate the safety and tolerability of SHR-4506 Injection in patients with malignant tumors and to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD).
Study Start Date: Aug., 2025
Study Type: INTERVENTIONAL
Condition:
Malignant Tumors of Adults
Intervention:
DRUG: SHR-4506 Injection
SHR-4506 injection.
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Disclaimer: Curated by HT Syndication....